News Image

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Provided By GlobeNewswire

Last update: Jun 9, 2025

- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks

Read more at globenewswire.com

ASCENDIS PHARMA A/S - ADR

NASDAQ:ASND (7/24/2025, 11:56:32 AM)

168.09

-2.05 (-1.2%)



Find more stocks in the Stock Screener

Follow ChartMill for more